BQCA (CAS 338747-41-4)
QUICK LINKS
Highly selective allosteric potentiator of the M1 muscarinic acetylcholine receptor (mAChR). Reduces the concentration of ACh required to activate M1 up to 129-fold and displays no potentiation, agonism or antagonism activity at other mAChRs at concentrations up to 100µM. Reverses scopolamine-induced memory deficits and increases blood flow to the cerebral cortex in mouse models. M1 activators slow the progression of Alzheimers disease. Induces β-arrestin recruitment to M1. At 100µM, it activated M1 in the absence of ACh to ca. 50% maximal response. At 10µM, it reduced the concentration of ACh required to displace radioligand by 45-fold. In vivo experiments were carried out in mice at 15 or 20mg/kg. The compound is cell permeable, brain penetrant and orally active.
BQCA (CAS 338747-41-4) References
Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease.: A. Fisher; Neurotherapeutics 5, 433 (2008) Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation.: L. Ma, et al.; PNAS 106, 15950 (2009)Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BQCA, 10 mg | sc-280627 | 10 mg | $71.00 | |||
BQCA, 50 mg | sc-280627A | 50 mg | $390.00 |